The results show that verapamil may be used in the treatment of type 1 diabetes

Recently, in a new study, the Shalev team used verapamil to conduct a randomized, double-blind, placebo-controlled clinical trial (http:// in humans for the first time The results showed that verapamil is a safe and effective drug for the treatment of type 1 diabetes (http:// The clinical trial monitored 24 patients between the ages of 18 and 45 over a period of one year Eleven patients (verapamil group) received treatment with verapamil and 13 patients (placebo group) received placebo All clinical trial participants were diagnosed with type 1 diabetes within three months of the start of the trial and continued to use the prescribed insulin pump throughout the study The Shalev team monitored the total daily insulin dose, the amount of insulin produced, the percentage change in insulin production, and HbA1c levels in the blood of the placebo and verapamil groups In addition, the number of hypoglycemic events experienced by these patients was recorded, and the percentage of time that each patient registered with the continuous glucose monitoring system (http:// was within the blood glucose range of Health (http:// The clinical results showed that verapamil could enhance the β cell function and insulin secretion of the adult patients with type 1 diabetes mellitus, reduce the need for external insulin injection and the frequency of hypoglycemic events Although the study was specifically aimed at adult patients diagnosed with type 1 diabetes within three months of the start of the trial, Shalev pointed out that long-term studies are needed in the future to determine the impact of verapamil on children with type 1 diabetes and those with the disease for more than three months In addition, the effect of verapamil on type 2 diabetes has not been tested or studied in prospective controlled clinical trials Shalev said research is needed to explore the potential of the drug to have a positive impact on type 2 diabetes However, in the mouse model of type 2 diabetes and recent epidemiological studies, the use of verapamil was associated with a lower risk of type 2 diabetes and better glycemic control.